Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab plus etoposide/carboplatin versus etoposide/carboplatin for neoadjuvant or conversion therapy in limited-stage small cell lung cancer
ChiCTR2300078911Phase 4Recruiting
- Sponsor
- Jinling Hospital
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adebelizumab, etoposide and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Jinling Hospital. Primary endpoint: Pathological complete remission rate. Started Dec 2023; status: recruiting.
02
Drugs
adebelizumabetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300078911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078911.